Claudin-1是原发性硬化性胆管炎的中介与治疗靶点
该研究通过五个PSC患者队列的单细胞RNA测序、空间转录组学和多路蛋白质组学,发现CLDN1在PSC肝组织中显著上调并与疾病进展相关。在PSC小鼠模型中,CLDN1特异性单克隆抗体或基因敲除可改善肝功能、减少纤维化和胆汁淤积。机制上,抗体治疗抑制了胆管细胞和肝细胞中的促炎和促纤维化信号。
要点
- PSC患者肝组织中CLDN1表达显著上调,与疾病进展相关。
- CLDN1特异性单抗或基因敲除在PSC小鼠模型中改善肝功能、减少纤维化和胆汁淤积。
- CLDN1单抗通过抑制促炎和促纤维化信号发挥作用,支持其临床开发。
核心结论
- CLDN1在PSC发病和胆管纤维化中具有功能作用,支持CLDN1特异性单抗作为PSC治疗策略的临床开发。
研究设计与样本
- 分析五个PSC患者队列的肝组织,采用单细胞RNA测序、空间转录组学和多路蛋白质组学。
- 在PSC和胆管病小鼠模型中进行CLDN1特异性单克隆抗体和基因功能缺失的概念验证研究。
- 在人细胞模型中进行扰动研究以探索机制。
主要发现
- PSC患者肝组织中CLDN1表达显著上调,并与疾病进展相关。
- 空间转录组学和蛋白质组学显示,病变胆管细胞和胆汁淤积性门管区肝细胞中CLDN1表达升高,伴促炎和促纤维化信号通路激活。
- 在PSC小鼠模型中,治疗性给予CLDN1特异性单抗或基因敲除可改善肝功能,减少肝胆纤维化和胆汁淤积。
- 机制研究表明,单抗治疗抑制了PSC肝组织中受扰的胆管细胞和肝细胞中的促炎和促纤维化信号。
临床怎么用
- CLDN1表达与PSC疾病分期和临床结局相关,可作为潜在生物标志物。
- CLDN1特异性单抗在临床前模型中显示疗效,支持进一步临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a cholangiopathy associated with a high risk of progression to end-stage liver disease and hepatobiliary cancer. Its pathogenesis remains poorly understood, and current clinical management offers limited therapeutic options, primarily liver transplantation. Claudin-1 (CLDN1), a transmembrane protein highly expressed in liver epithelial cells, plays a critical role in cell-cell communication and signaling. We aimed to investigate the functional role of CLDN1 as both a mediator and potential therapeutic target for PSC using patient cohorts alongside murine and patient-derived intervention models. METHODS: CLDN1 expression patterns and associated cellular phenotypes were analyzed in liver tissues from five PSC patient cohorts using single-cell RNA sequencing, spatial transcriptomics, and multiplex proteomics. Proof-of-concept studies employing CLDN1-specific monoclonal antibodies (mAbs) and genetic loss-of-function approaches were performed in state-of-the-art mouse models of PSC and cholangiopathies. Perturbation studies in human cell-based models were conducted to explore underlying mechanisms. RESULTS: In liver tissues from patients with PSC, CLDN1 expression was markedly upregulated and correlated with disease progression. Spatial transcriptomics and proteomics revealed elevated CLDN1 expression in diseased cholangiocytes and cholestatic periportal hepatocytes, accompanied by activation of pro-inflammatory and pro-fibrotic signaling pathways. Therapeutic administration of CLDN1-specific mAbs or genetic knockout improved liver function in PSC mouse models by reducing hepatobiliary fibrosis and cholestasis. Mechanistic studies indicated that mAb treatment inhibited pro-inflammatory and pro-fibrotic signaling in cholangiocytes and hepatocytes perturbed in PSC liver tissues. CONCLUSIONS: These findings demonstrate a functional role for CLDN1 in the pathogenesis of PSC and biliary fibrosis. In vivo proof-of-concept studies, combined with expression analyses in patients with PSC, support the clinical development of CLDN1-specific mAbs as a therapeutic strategy for PSC. IMPACT AND IMPLICATIONS: Primary sclerosing cholangitis (PSC) is a chronic fibrosing cholangiopathy with limited therapeutic options. We identified the cell surface protein Claudin-1 as a key mediator and potential therapeutic target for PSC. In patients, Claudin-1 expression correlates with disease stage and clinical outcomes. Conditional liver epithelial-specific Claudin-1 knockout in mice reduced liver injury, fibrosis, and cholestasis. Monoclonal antibodies targeting Claudin-1 inhibited fibrosis, cholestasis, and the ductular reaction across advanced PSC mouse models by suppressing pro-inflammatory and fibrogenic signaling. These preclinical findings support the clinical development of Claudin-1-specific antibodies for PSC treatment and have significant implications for physicians, researchers, and drug developers in the field of biliary disease.
引用
- Del Zompo F, Crouchet E, Ostyn T, et al. Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis. J Hepatol. 2025. PMID: 40846184. doi:10.1016/j.jhep.2025.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。